Author

Rajsi V. Parikh

Observed name: R. Parikh

Institution: Gujarat University

Observed institutions: Rutgers, The State University of New Jersey, Gujarat University, University of Kansas, Rutgers Cancer Institute

ORCID: 0000-0003-0766-7337

Observed ORCID: 0000-0003-0766-7337

OpenAlex ID: A5050048657

Investigation on Anti‐plasmodial Agents Against wild‐type Pf DHFR Through In Silico Computational Tools

2024 · Rajsi V. Parikh, Disha V. Pandya, et al. · ChemistrySelect · 6

1024P Baseline biomarkers associated with clinical benefit in patients with solid tumors refractory to immune checkpoint inhibitors (ICIs) treated with live biotherapeutic MRx0518 in combination with pembrolizumab

2021 · E.R. Parra, M. Adriani, et al. · Annals of Oncology · 5

RETRACTED ARTICLE: The scaffold protein disabled 2 (DAB2) and its role in tumor development and progression

2024 · Disha V. Pandya, Rajsi V. Parikh, et al. · Molecular Biology Reports · 2

Stromal tumors: Exploring rare ovarian cancer types

2025 · Rajsi V. Parikh, Disha V. Pandya, et al. · Elsevier eBooks

Retraction Note: The scaffold protein disabled 2 (DAB2) and its role in tumor development and progression

2025 · Disha V. Pandya, Rajsi V. Parikh, et al. · Molecular Biology Reports

Radiotherapy utilization and outcomes from a contemporary study of brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin lymphoma

2024 · B. Hoppe, S. Castellino, et al. · International Journal of Particle Therapy

Tolerability of lapatinib in combination with taxanes (T) in 507 patients with breast cancer (BC)

2008 · J. Crown, H.A. Burris, et al. · European Journal of Cancer Supplements

Works count: 8

Citation count: 13

H-index: 2

I10-index: